Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
Gemma Currie(British Heart Foundation), Patrick B. Mark(Queen Elizabeth University Hospital), David Preiss(Medical Research Council), Christian Delles, Charles J. Ferro(Queen Elizabeth Hospital Birmingham), Nicola C. Edwards(NIHR Surgical Reconstruction and Microbiology Research Centre), Mohammad G. Saklayen(Wright State University), Sonia Oveisi(Qazvin University of Medical Sciences), Morten Lindhardt(Steno Diabetes Centers), Alan G. Jardine(Western Infirmary), Hiroshi Ohtsu(Juntendo University), Toshiro Fujita(The University of Tokyo), Peter Rossing(Steno Diabetes Centers), Alison Taylor(British Heart Foundation), Lene Boesby(University of Copenhagen), Anton H. van den Meiracker(Erasmus MC), John Townend(Queen Elizabeth Hospital Birmingham)
Cited by 209
Related Papers
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
The Global Epidemic of the Metabolic Syndrome
|Current Hypertension Reports|2018|4k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
|European Heart Journal|2024|1.9k